Advanced hybrid closed-loop systems offer improved glucose control and represent the most advanced form of insulin delivery currently available for diabetic patients; however, the extensive manual input required by the user in the form of carbohydrate counting and bolus delivery, alarm fatigue, fear of hypoglycemia, and diabetes-related psychological distress has highlighted the need for further research into newer technologies [58]. The gene discussed is INS; the disease is diabetes mellitus.